Рецепт. 2022; : 31-45
Тиотриазолин у пациентов со среднетяжелой клинической формой инфекции COVID-19 и высоким уровнем лактатдегидрогеназы: эффективность и безопасность
https://doi.org/10.34883/PI.2022.25.1.010Аннотация
Использование Тиотриазолина у пациентов со среднетяжелой пневмонией при инфекции COVID-19 на стационарном этапе позволило уменьшить повреждение клетки со снижением уровня ЛДГ в основной группе с 1106,9±376,0 до 659,5±277,6 Ед/л (–447,4±460,9 Ед/л) против динамики от 845,4±271,9 до 744,8±313,4 Ед/л (–100,6±487,9 Ед/л) в контрольной группе (р=0,025) при отсутствии побочных эффектов либо осложнений. Применение лекарственного средства Тиотриазолин у пациентов со среднетяжелой пневмонией позволило достоверно улучшить качество жизни пациентов: интегральные показатели физического здоровья (IPH) – в основной группе 68,5±20,1 балла против 49,5±24,1 балла в контрольной группе, и психического здоровья (IMH) – 72,7±18,2 балла в основной группе против 52,8±23,3 балла в контрольной группе соответственно, р=0,001.
Список литературы
1. Attaway A.H. (2021) Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. doi: 10.1136/bmj.n436.
2. Recommendations (temporary) on the organization of medical care for patients with COVID-19 infection (Order of the Ministry of Health of the Republic of Belarus 11.11.2021 No. 1424) (in Russian).
3. Krishnan Shuba (2021) Metabolic perturbation associated with COVID-19 disease and SARS-CoV-2 replication. Mol. Cell Proteomics. Available at: https://doi.org/10.1016/j.mcpro.2021.100159
4. Salivonchik D., Salivonchik E. (2020) Energeticheskij krizis pri COVID-19: diagnostika i lechenie [Energy Crisis in COVID-19: Diagnosis and Treatment]. Recept, 5, pp. 680–693.
5. Farhana A., Lappin S.L. (2021) Biochemistry, lactate dehydrogenase. Treasure Island (FL): StatPearls.
6. Henry B.M., Aggarwal G., Wong J. (2020) Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med., 38, pp. 1722–1726. doi: 10.1016/J.AJEM.2020.05.073.
7. Martha J.W., Wibowo A., Pranata R. (2021) Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. Postgrad Med J. doi: 10.1136/postgradmedj-2020-139542.
8. Martinez-Urbistondo M., Mora-Vargas A., Expósito-Palomo E. (2020) Inflammatory-related clinical and metabolic outcomes in COVID-19 patients. Mediat Inflamm., 2020: 2914275. doi: 10.1155/2020/2914275.
9. Shi J., Li Y., Zhou X. (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested casecontrol study. BMC Med., 18: 168. doi: 10.1186/s12916-020-01633-7.
10. Wu M., Yao L., Wang Y. (2020) Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res., 21: 171. doi: 10.1186/s12931-020-01427-8.
11. Yan H., Liang X., Du J. (2021) Proteomic and metabolomic investigation of serum lactate dehydrogenase elevation in COVID-19 patients. Proteomics. doi: 10.1002/pmic.202100002.
12. Zhou Y., Ding N., Yang G. (2020) Serum lactate dehydrogenase level may predict acute respiratory distress syndrome of patients with fever infected by SARS-CoV-2. Ann Transl Med., 8: 1118. doi: 10.21037/atm-20-2411.
13. Szarpak L. (2021) Lactate dehydrogenase level as a COVID-19 severity marker. Am J Emerg Med., 45, pp. 638–639. doi: 10.1016/j.ajem.2020.11.025.
14. Shi Jichan (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med., 18 (1): 168. doi: 10.1186/s12916-020-01633-7.
15. Poggiali E. (2020) Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta., 509, pp. 135–138. doi: 10.1016/j.cca.2020.06.012.
16. Faloppi L., Bianconi M., Giampieri R. (2015) The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 6, pp. 35087–35094. doi: 10.18632/oncotarget.5197.
17. Feng Y., Xiong Y., Qiao T., Li X., Jia L., Han Y. (2018) Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med., 7 (12), pp. 6124–6136.
18. Liberti M.V., Locasale J.W. (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci., 41, pp. 211–218. doi: 10.1016/j.tibs.2015.12.001.
19. Salivonchyk D., Salivonchyk E. (2021) Energy covid-19 collapse: new diagnostic markers, treatment aspects. Journal of cardiorespiratory research., vol. 2, issue 2, pp. 68–76.
20. Salivonchik D. (2021) COVID-19: poshagovye strategii lecheniya. Problemy zdorov’ya i ekologii, vol. 18, no 2, pp. 155–162.
21. Jenkinson C., Coulter A., Wright L. (1993) Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. Br. Med. J., vol. 306, pp. 1437–1440.
22. The WHOQOL Group (1995) The World Health Organization Quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc. Sci. Med., vol. 41, pp. 1403–1409.
23. Salivonchik D. (2021) Effektivnost’ i bezopasnost’ profilakticheskoj antikoagulyacii u pacientov pri COVID-19-pnevmonii. Kardiologiya v Belarusi, vol. 13, no 3, pp. 336–353.
24. Kumar P., Nagarajan A., Uchil P.D. (2018) Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. doi: 10.1101/pdb.prot095497.
25. Valenza F. (2005) Lactat as a marker of energy failure in critically ill patients: hypothesis. Critical Care, vol. 5, no 6, pp. 588–593.
26. Mazur I. (2005) Tiotriazolin. Zaporozh’e. 146 p.
27. Netyazhenko V., Mal’chevskaya T. (2010) Vozmozhnosti metabolicheskoj terapii v lechenii ishemicheskoj bolezni serdca: opyt dvojnogo slepogo randomizirovannogo mul’ticentrovogo issledovaniya [Possibilities of metabolic therapy in the treatment of coronary heart disease: the experience of a double-blind, randomized, multicenter study]. Listapad, no 22 (251), pp. 1–5.
Recipe. 2022; : 31-45
Thiotriazoline in Patients with Moderate Clinical COVID-19 Infection and High Levels of Lactate Dehydrogenase: Efficiency and Safety
https://doi.org/10.34883/PI.2022.25.1.010Abstract
The use of Tiotriazoline in patients with moderate pneumonia with COVID-19 infection at the inpatient stage made it possible to reduce cell damage with a decrease in LDH levels in the main group from 1106.9±376.0 to 659.5±277.6 U/l (–447.4±460.9 U/l) versus dynamics from 845.4±271.9 to 744.8±313.4 U/l (–100.6±487.9 U/l) in the control group (p=0.025) with no side effects or complications. The use of the drug Thiotriazolin in patients with moderate pneumonia made it possible to significantly improve the quality of life of patients - integral indicators of physical health (IPH) in the main group 68.5±20.1 points versus 49.5±24.1 points in the control group, and mental health (IMH) 72.7±18.2 points in the main group versus 52.8±23.3 points in the control group, respectively, p=0.001.
References
1. Attaway A.H. (2021) Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. doi: 10.1136/bmj.n436.
2. Recommendations (temporary) on the organization of medical care for patients with COVID-19 infection (Order of the Ministry of Health of the Republic of Belarus 11.11.2021 No. 1424) (in Russian).
3. Krishnan Shuba (2021) Metabolic perturbation associated with COVID-19 disease and SARS-CoV-2 replication. Mol. Cell Proteomics. Available at: https://doi.org/10.1016/j.mcpro.2021.100159
4. Salivonchik D., Salivonchik E. (2020) Energeticheskij krizis pri COVID-19: diagnostika i lechenie [Energy Crisis in COVID-19: Diagnosis and Treatment]. Recept, 5, pp. 680–693.
5. Farhana A., Lappin S.L. (2021) Biochemistry, lactate dehydrogenase. Treasure Island (FL): StatPearls.
6. Henry B.M., Aggarwal G., Wong J. (2020) Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med., 38, pp. 1722–1726. doi: 10.1016/J.AJEM.2020.05.073.
7. Martha J.W., Wibowo A., Pranata R. (2021) Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. Postgrad Med J. doi: 10.1136/postgradmedj-2020-139542.
8. Martinez-Urbistondo M., Mora-Vargas A., Expósito-Palomo E. (2020) Inflammatory-related clinical and metabolic outcomes in COVID-19 patients. Mediat Inflamm., 2020: 2914275. doi: 10.1155/2020/2914275.
9. Shi J., Li Y., Zhou X. (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested casecontrol study. BMC Med., 18: 168. doi: 10.1186/s12916-020-01633-7.
10. Wu M., Yao L., Wang Y. (2020) Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res., 21: 171. doi: 10.1186/s12931-020-01427-8.
11. Yan H., Liang X., Du J. (2021) Proteomic and metabolomic investigation of serum lactate dehydrogenase elevation in COVID-19 patients. Proteomics. doi: 10.1002/pmic.202100002.
12. Zhou Y., Ding N., Yang G. (2020) Serum lactate dehydrogenase level may predict acute respiratory distress syndrome of patients with fever infected by SARS-CoV-2. Ann Transl Med., 8: 1118. doi: 10.21037/atm-20-2411.
13. Szarpak L. (2021) Lactate dehydrogenase level as a COVID-19 severity marker. Am J Emerg Med., 45, pp. 638–639. doi: 10.1016/j.ajem.2020.11.025.
14. Shi Jichan (2020) Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med., 18 (1): 168. doi: 10.1186/s12916-020-01633-7.
15. Poggiali E. (2020) Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta., 509, pp. 135–138. doi: 10.1016/j.cca.2020.06.012.
16. Faloppi L., Bianconi M., Giampieri R. (2015) The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 6, pp. 35087–35094. doi: 10.18632/oncotarget.5197.
17. Feng Y., Xiong Y., Qiao T., Li X., Jia L., Han Y. (2018) Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med., 7 (12), pp. 6124–6136.
18. Liberti M.V., Locasale J.W. (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci., 41, pp. 211–218. doi: 10.1016/j.tibs.2015.12.001.
19. Salivonchyk D., Salivonchyk E. (2021) Energy covid-19 collapse: new diagnostic markers, treatment aspects. Journal of cardiorespiratory research., vol. 2, issue 2, pp. 68–76.
20. Salivonchik D. (2021) COVID-19: poshagovye strategii lecheniya. Problemy zdorov’ya i ekologii, vol. 18, no 2, pp. 155–162.
21. Jenkinson C., Coulter A., Wright L. (1993) Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. Br. Med. J., vol. 306, pp. 1437–1440.
22. The WHOQOL Group (1995) The World Health Organization Quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc. Sci. Med., vol. 41, pp. 1403–1409.
23. Salivonchik D. (2021) Effektivnost’ i bezopasnost’ profilakticheskoj antikoagulyacii u pacientov pri COVID-19-pnevmonii. Kardiologiya v Belarusi, vol. 13, no 3, pp. 336–353.
24. Kumar P., Nagarajan A., Uchil P.D. (2018) Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. doi: 10.1101/pdb.prot095497.
25. Valenza F. (2005) Lactat as a marker of energy failure in critically ill patients: hypothesis. Critical Care, vol. 5, no 6, pp. 588–593.
26. Mazur I. (2005) Tiotriazolin. Zaporozh’e. 146 p.
27. Netyazhenko V., Mal’chevskaya T. (2010) Vozmozhnosti metabolicheskoj terapii v lechenii ishemicheskoj bolezni serdca: opyt dvojnogo slepogo randomizirovannogo mul’ticentrovogo issledovaniya [Possibilities of metabolic therapy in the treatment of coronary heart disease: the experience of a double-blind, randomized, multicenter study]. Listapad, no 22 (251), pp. 1–5.
